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INTRODUCTION
Most mammalian cells acquire cholesterol via the uptake of circulating LDLs. After binding to the LDL receptor or other family members, LDLs are delivered to early endosomes where they are uncoupled from their receptor [1] . While the receptor is recycled to the plasma membrane for another round of utilization, LDLs are packaged into maturing multivesicular endosomes, and transported towards late endosomes and lysosomes [2] . In these late endocytic compartments, the LDL particle is disaggregated upon degradation of associated apoproteins, and cholesteryl esters are de-esterified by acidic lipase LIPA. From there, free cholesterol redistributes to intracellular membranes, including the endoplasmic reticulum where it controls the expression of cholesterol-dependent gene via the SREBP pathway [3, 4] .
However, the mechanisms that regulate the endosomal cholesterol content, and control its translocation across the endosomal membrane and further export towards other destinations are not clear. When mutated, two genes NPC1 and NPC2 are responsible for the cholesterol storage disease Niemann-Pick type C, but the functions of the NPC1 and NPC2 proteins remain incompletely understood [5] .
We previously observed that in NPC cells cholesterol accumulates in late endosomes containing lysobisphosphatidic acid (LBPA) [6, 7] , also referred to as bis(monoacylglycero)phosphate (BMP). This atypical phospholipid accounts for approximately 15 Mol% of total phospholipids in the multivesicular late endosomes of BHK cells, where it abounds within intralumenal membranes, and is not detected in other subcellular compartments [7, 8] . In addition to this uncommon distribution, LBPA also exhibits an unusual stereo-configuration [9, 10] , and its metabolism is poorly understood [11, 12] .
After de-esterification, free LDL-derived cholesterol is incorporated into membrane of LBPAcontaining late endocytic compartments. In fact, our data indicate that LBPA plays a direct role in regulating the cholesterol flux through endosomes. Interfering with LBPA functions causes cholesterol accumulation in late endosomes, phenocopying NPC [6, 13] , and inhibits Wnt-induced biogenesis of lipid droplets [14] . In this paper, we describe a strategy to identify compounds that influence levels and/or distribution of LBPA. We identify thioperamide as a novel modulator of LBPA levels in late endosomes and show that it decreases the cholesterol overload in fibroblasts from NPC patients and in NPC null mice.
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RESULTS
High content screen to identify compounds that modulate LBPA
Our initial goal was to identify compounds that influence LBPA using a monoclonal antibody against LBPA in a high content image-based screen [7] . Since free LDL-derived cholesterol is released in late endosomes containing LBPA (Fig 1A) , and given our observations that cholesterol is functionally linked to LBPA [6] , we also monitored cholesterol, using the polyene macrolide filipin, which binds cholesterol and conveniently emits in the UV range. As additional markers for cell segmentation during automated image analysis, we used propidium iodide to label nuclei and cell tracker to label the cytoplasm.
The screen was carried out with the Prestwick library of FDA-approved drugs (http://www.prestwickchemical.com/libraries-screening-lib-pcl.html; and see Table EV1 and Table EV2 ), because of high chemical and pharmacological diversity, low toxicity, known bioavailability and structures, and also because some target data are available. Fig 1C shows an example of a 384-well plate stained for cholesterol (green) and LBPA (red) with 4 micrographs stitched together per well. As negative controls, all wells in one column were treated with DMSO only (Fig 1C, left of the plate), and as positive controls, all wells in another column were treated with the pharmacological agent U18666A (Fig 1C, right of the plate), a charged sterol analog that mimics NPC [15] , binds the NPC1 protein [16] , and causes the accumulation of both cholesterol and LBPA in late endosomes [6, 14] (Fig 1E) . The broad dynamic range of the detection system and its robustness, as already revealed in our previous RNAi screens with the same detection system [14] , are illustrated by the staining with both markers in U18666A-treated vs. control cells (Fig 1C, DMSO left of the plate; Fig 1E) While most compounds had no effect on the two lipids as anticipated, the majority of the compounds that did have an effect caused a concomitant increase in both cholesterol and LBPA, much like U18666A (Fig 1B) . However, a few compounds caused an apparent increase in LBPA staining with minimal effect on cholesterol levels -a phenotype particularly striking in cells treated with thioperamide maleate (Fig 1C lower well in the boxed area, and Fig 1B, pink dot). We thus decided to focus on thioperamide and to further characterize the effects of this compound.
Effects of thioperamide on LBPA levels
The selective increase in LBPA, but not cholesterol, is well illustrated in high magnification views of the cells treated with thioperamide (Fig 1E) . Automated, unbiased quantification of the screen data confirmed that LBPA staining intensity was increased highly significantly in thioperamide-treated cells without any visible toxic effect, while both LBPA and cholesterol levels increased in the presence of U18666A (Fig 1E) as expected. Similarly, trimeprazine caused a marked increase in LBPA (Fig 1 D-E ; light blue in Fig 1B) , but also raised cholesterol levels to the same extent as U18666A (Fig 1D-E) .
In addition, thioperamide affected equally different cells types of human or rodent origin (Fig   2A) . Consistent with our imaging data (Fig 1) , a biochemical analysis confirmed that, in marked contrast to U18666A, thioperamide did not affect the levels of free cholesterol, esterified cholesterol and total cholesterol, when compared to controls (Fig 2B) . Moreover, automated unbiased quantification further demonstrated that the cholesterol content of individual LBPA-endosomes after thioperamide treatment was very similar to the DMSO controls -and also to most cells treated with Prestwick compounds (Fig 2C) . Finally, an analysis by electron microscopy showed that the ultrastructure of individual endosomes looked very similar in thioperamide-treated cells when compared to controls (Fig EV1A) . However, immunogold labeling of cryosections using the anti-LBPA antibody confirmed that the amounts of LBPA in multivesicular late endosomes increased in thioperamide-treated cells (Fig 3A, pseudocoloured individual endosomes and uncolored originals in Fig EV1B; double-blind quantification in Fig 3B) .
While differences in staining intensity alone already revealed major differences in the effects of some compounds, the automated image analysis pipeline captured additional parameters, (e.g size, area, integrated intensity, average intensity, object count), to describe and compare the various staining patterns. Given the large set of parameters, the combination of variables was transformed into principal components to best explore the phenotypic space. The principal components analysis (PCA) confirmed that most compounds had no significant effect on cholesterol and LBPA, while all U18666A-treated cells (green, Movie EV1) clustered together far away from the bulk (white, Movie EV1). Interestingly, the PCA also demonstrates that the thioperamide phenotype (pink, Movie EV1) is set far away from all other compounds, including the positive control U18666A or any compound affecting LBPA or cholesterol. These observations further confirm the notion that the cellular effects of thioperamide are unique and remarkable.
Effects of thioperamide on endosome distribution
The differences observed in the PCA space between thioperamide vs. U18666A or trimeprazine were not only due to differences in the cholesterol content of LBPA-containing endosomes, but also in their subcellular distribution. After U18666A or trimeprazine treatment, LBPA-positive late endosomes loaded with cholesterol were typically clustered in the perinuclear region (Fig 1E) . This distribution agrees well with previous observations by us [13] and others [17, 18] that cholesterol accumulation in NPC cells paralyses late endosomes at the microtubule minus-ends, close to the nucleus. In marked contrast, thioperamide did not seem to cause perinuclear clustering of LBPA-endosomes (Fig 1E) , in line with our observations that it did not affect cholesterol (Fig 1C, Fig 2C) . Automated unbiased quantification of all cells treated with Prestwick compounds confirmed that U18666A and trimeprazine caused a highly significant increase in perinuclear LBPA staining (Fig 3C) . By contrast, thioperamide had essentially no effect on endosome distribution, much like DMSO in controls or most Prestwick compounds (Fig 3C) . In addition, counting the number of individual LBPA-positive structures after treatment with Prestwick compounds, showed that thioperamide was present on the side of the distribution opposite to trimeprazine or U18666A (z-factors shown in Fig 3D) -the distribution is relatively noisy because of cell-tocell variation. Indeed, LBPA-endosomes clustered in the vicinity of the nucleus after trimeprazine or U18666A treatment were no longer well resolved, resulting in an apparent decrease in the number of labeled endosomes.
Effects of thioperamide on endosome functions
We then investigated whether thioperamide had any effect on other endosomal functions.
No change was observed in the amounts of markers of early (EEA1, transferrin receptor) or late (LAMP1, CD63) endocytic compartments (Fig EV2A) . Neither was the distribution of these markers changed by the drug (Fig EV2A) -the clustering effects of U18666A are shown for comparison. Similarly, thioperamide did not affect the endo-lysosome acidification capacity 7 or the number of acidic endo-lysosomes (Fig EV2C) -the effects of the V-ATPase inhibitor bafilomycin A1 is shown after a short (2h) treatment for comparison. During infection with vesicular stomatitis virus (VSV), the release of viral RNA into the cytoplasm depends on functionally intact endosomes [19] [20] , and is inhibited by cholesterol accumulation in endosomes [21] . After incubating cells for 3h with recombinant VSV expressing GFP-tagged P-protein [22] [23] at a low physiologically relevant MOI (1.0), no difference could be observed between thioperamide-and mock-treated control cells (Fig EV2B) . Moreover, the degradation of the epidermal growth factor (EGF) receptor in cells challenged with EGF, occurred with identical kinetics in cells treated with thioperamide and in controls (Fig EV2D; quantification by automated microscopy shown in the bar graph). Altogether, these data demonstrate that thioperamide increases LBPA levels in late endosomes highly selectively without affecting their cholesterol content, and that endosomes and lysosomes of thioperamide-treated cells are functionally intact.
Thioperamide targets the histamine receptor HRH3
Thioperamide is reported to act as an inverse agonist of the histamine receptor H3 (HRH3) [24] but it also acts on HRH4, another member of the same receptor family [25] . HRH3 is closely related to HRH4 (37% sequence identity) and more distantly related to HRH1 or HRH2 (21% sequence identity), the two other members of this family. We thus compared the effects of compounds known to target histamine receptors, including those that were already present in the Prestwick library, as well as a small library of additional HRH3/HRH4 antagonists and histamine analogs (Table EV3) . Strikingly, 10 out of 12 compounds targeting HRH3 or HRH4, which all act as antagonists or inverse agonists, exhibited a thioperamide-like increase in LBPA without changing cholesterol levels (Fig 4A) . These observations strongly argue against the notion that the increase in LBPA levels was caused by some off-target effects of thioperamide, since the chemical scaffolds of these compounds are different. In marked contrast, LBPA accumulation was observed with only 2 out of the 26 compounds against HRH1, and with none of the 5 compounds that target HRH2 (Fig 4A) . Neither did histamine (not shown) or any histamine receptor agonist that was tested ( Fig 4A and Table   EV3 ).
We also found that pitolisant, which was not in the Prestwick library (Table EV3) , increased LBPA levels to a similar extent as thioperamide, without affecting cholesterol levels ( Fig 2B and Fig 4B) , again much like thioperamide. Moreover, the dose-response profiles (Fig EV3A) and time-courses (Fig EV3B) of LBPA accumulation were similar with both thioperamide and pitolisant. However, treatment with pitolisant reduced the cell number at long time-points (new Fig EV3C) , suggesting that the drug may have some cytotoxic effects. We thus centered our efforts on thioperamide alone.
Further support for the notion that thioperamide targets HRH3 as an inverse agonist came from the observations that levels of LBPA and HRH3 were inversely-correlated. Indeed, in a mixed population of cells expressing GFP-tagged HRH3 (Fig 4F) , the cellular intensity of the LBPA signal is skewed towards cells expressing low levels of HRH3-GFP and vice-versa (Fig 4G) , indicating that LBPA levels are low in cells expressing high HRH3-GFP levels and high in cells expressing low HRH3-GFP levels. These observations were confirmed using cells stably expressing HRH3-GFP. In these cells, HRH3-GFP could be efficiently depleted after knockdown with 4 different siRNAs (Fig 4C, quantification in Fig 4E) . Again, LBPA and HRH3-GFP levels were anti-correlated, and HRH3-GFP depletion was accompanied with a concomitant increase in LBPA levels (Fig 4D-E) .
Thioperamide reduces cholesterol overload in NPC cells
Cholesterol accumulates in late endocytic compartments of NPC cells, eventually leading to a pathological enlargement of these compartments -a characteristic of lysosomal storage disorders. Concomitant with this increase in endosomal volume, protein and lipid [21] , total LBPA levels are also increased [6] . The accumulation of storage materials in NPC endosomes eventually leads to a traffic jam and a collapse of endosomal membrane dynamics [26, 27] .
Given the role of LBPA in endosomal cholesterol transport [6, 14, 28] , we reasoned that the capacity of LBPA to accommodate -or buffer -excess cholesterol may eventually become limiting in NPC endosomes.
To test the effects of thioperamide in NPC cells, we used three fibroblast lines obtained from patients with well-established mutations in the NPC1 or NPC2 gene. In all three cell lines, thioperamide caused after 72h a very significant decrease in cholesterol levels (Fig 5A,   9 quantification in Fig 5B at 72h) . In contrast to control cell lines (Fig 1 and Fig 2A) , LBPA levels were also decreased in NPC cell lines after a 72h treatment (Fig 5B) . This decrease was not due to some toxic effects of the compound in NPC1 or NPC2 cells after 48h (Fig 5D) or 72h ( Fig 5E) . If anything, the number of thioperamide-treated NPC cells after 72h was somewhat higher than the controls, suggesting that drug may increase cell survival. We therefore hypothesized that the effects of the drug on LBPA levels may be obscured in NPC cells by the beneficial decrease in storage of cholesterol and other lipids including LBPA. Indeed, a significant increase in LBPA levels was transiently observed at a shorter time-point, before changes in cholesterol could be detected (Fig 5B at 48h ) -this increase is particularly striking, since even before thioperamide addition, LBPA levels are already much higher in NPC cells when compared to controls [6] (see also LBPA quantification in NPC1 mice, Fig 5G) . The simplest interpretation may be that, much like in other cell types, thioperamide increases LBPA levels in NPC cells, thus facilitating cholesterol mobilization, consistent with previous findings [28] , which in turn reduces storage materials in endosomes and restores physiological levels of LBPA and other lipids.
An analysis by mass spectrometry showed that total cellular cholesterol normalized to total cellular lipids was also reduced by thioperamide treatment of all 3 NPC cell lines (Fig 5C) . At the total cellular level (Fig 5C) , the effects of the drug appear less prominent than at the endosomal level (Fig 5B) , because in NPC fibroblasts, the amounts of cholesterol accumulated in endosomes corresponds only to a fraction of total cellular cholesterol [29] . We compared the reduction in cholesterol levels to treatment with cyclodextrin, currently considered to be one of the -if not the -most efficient protocol to reduce cholesterol levels in cultured cells [5, 30] . Cyclodextrin also decreases the progression of neurological disorders in NPC1 patients after intrathecal injection [31] . Remarkably, thioperamide reduced cholesterol levels as efficiently as cyclodextrin ( Fig 5C) . In addition, the feedback transcriptional regulation of cholesterol metabolism via the sterol regulatory element-binding protein (SREBP) pathway is defective in NPC cells [32] [33] [34] (see also Fig 6A) . To test the effects of thioperamide, we used NPC1 and NPC2 knockout cells generated using CRISPR/Cas9 [35] . Much like cyclodextrin [35] , thioperamide was able to partially correct the defect in the transcriptional regulation of two canonical cholesterol-dependent genes, the LDL receptor and HMG CoA reductase in these NPC1 and NPC2 KO cells (Fig 6A) . By contrast, thioperamide treatment did not affect the expression levels of proteins involved in the transfer of cholesterol from endosome to the ER or in endosome-ER membrane contact sites (Fig EV4) , including FYCO1 [36] , ANXA1 [37] , STARD3/MLN64 [38] , ORP1l, VAPA and VAPB [39, 40] .
Effects of thioperamide in Npc1
−/− mice Finally, we tested the effects of thioperamide in mice lacking NPC1. As anticipated, the liver of Npc1 −/− mice showed significant accumulation of cholesterol, approximately 20X higher than livers from WT littermates ( Fig 6B) . LBPA was quantified by mass spectrometry after efficient separation from phosphatidylglycerol (PG), because the two lipids are isobaric ( Fig   EV5A) . Much like cholesterol, LBPA also accumulated approximately 10X (Fig 6B) .
Interestingly, the mass spectrometry analysis also revealed the presence of a triple acylated version of LBPA, semilysobisphosphatidic acid (sLBPA) [41] , which could be well separated from LBPA and PG ( Fig EV5B) . sLBPA also accumulated significantly, increasing from less than 0.05% of total phospholipids in WT liver to 0. WT and Npc1 −/− mice, which model the most aggressive early onset form of the disease [42] , were then treated with thioperamide. The treatment started at weaning (3 weeks of age) and continued until they reached the humane end-point (loss of 10% body weight within 24hrs), to minimize suffering. At that point, thioperamide did not significantly improve the life span, motor function/rearing or high frequency tremor of Npc1 −/− mice, although some benefits were observed when combined with Miglustat ( Fig EV9C) -the only compound available as a treatment against NPC in Europe, but not in the US, which prolongs life but does not arrest disease progression [43] . LBPA was marginally decreased in drug-treated Npc1 −/− liver ( Fig   6B) , and sLBPA unaffected (Fig EV6A) , while the acyl chain composition remained unchanged (Fig EV7A-B) . Strikingly, however, the cholesterol levels in the Npc1 −/− mouse liver were significantly reduced by the thioperamide treatment (Fig 6B) , as in NPC fibroblasts (Fig 5C) . In contrast to liver, total cholesterol levels in the brain of Npc1 −/− mice were similar to wt (Fig   EV10A) , as expected [44, 45] , perhaps reflecting the asymmetric distribution of cholesterol in NPC neurons [46] . However, much like in liver, LBPA amounts ( Fig EV10B) and acyl chain composition ( Fig EV10C) were significantly changed. Altogether, these data suggest that in NPC cell lines and Npc1 −/− liver cells thioperamide facilitates cholesterol mobilization, presumably by transiently increasing LBPA levels, similar to other cells (Fig 1-3 More work will be needed to establish unambiguously what is the mode of action of thioperamide, as well as the link between LBPA and cholesterol. However, some speculations are already possible. First, the notion that thioperamide acts by modulating the activity of the NPC1 or NPC2 proteins can be ruled out, given the effects of the drug in NPC cells and mice.
It also seems fairly unlikely that thioperamide exerts its direct and selective effect on cholesterol, by modulating the biochemical or biophysical properties of the cholesterol-laden bilayer after partitioning into endosomal (LBPA-containing) membranes. Indeed, the drug raises LBPA levels specifically without affecting any other endosomal function or protein.
Moreover, this view is not easily reconciled with observations that LBPA levels are also increased by other inhibitors of the HRH3 receptor that do not share a common backbone with thioperamide. It should be noted that HRH3 and HRH4 are expressed in most tissues, including liver and brain, as revealed by an analysis using Genevestigator tools that combine thousands of microarray experiments (https://www.genevestigator.com/gv/index.jsp).
Hence, the simplest interpretation is that binding of thioperamide to the HRH3 receptor on the cell surface as inverse agonists [24] , increases LBPA levels by stimulating biosynthesis or inhibiting turnover -an issue not easily solved since the metabolic regulation of LBPA remains mysterious and the enzymes involved in biosynthesis and turnover are not known [11, 12] . High LBPA levels in turn may contribute to fluidify or buffer cholesterol in endosomal membranes, thereby facilitating its mobilization and subsequent export to cellular destinations.
In NPC cells, before the addition of thioperamide, the levels of LBPA are already strongly elevated [6] (see Fig 6D) , as part of the general expansion of late endosome volume, protein and lipid [21] . This enlargement of the endosomal system presumably reflects the attempt to compensate for the accumulation of storage materials. Eventually, however, the system collapses under the excess load, leading to a traffic jam and a breakdown of endosomal membrane dynamics [26, 27] . Given its role in endosomal cholesterol transport [6, 14, 28 ], we propose that LBPA then becomes limiting, because its capacity to accommodate -or buffer -excess cholesterol in NPC endosomes is overwhelmed. Alternatively, LBPA may play a more direct role in cholesterol mobilization and transport. In any case, it is also tempting to speculate that the highly selective changes in LBPA and sLBPA acyl chain compositionshorter chains and reduced number of double bonds -observed in NPC mouse liver reflect some additional adjustment in membrane chemical and physical properties to better accommodate changes due to cholesterol accumulation [47] [48] [49] [50] .
At first sight, it may appear counter-intuitive that thioperamide acts in NPC cells and mice via LBPA, since the drug decreases LBPA levels in NPC cells after 72h ( Fig 6B) and in Npc1 −/− mouse liver at least to some extent (Fig 6E) . However, our model predicts that LBPA will only be transiently increased in NPC cells. High LBPA levels will alleviate cholesterol overload, which in turn will reduce storage and revert the cell response to the endosome overload, resulting in decreased levels of LBPA and other endosomal lipids and proteins. Indeed, as predicted, a significant increase in LBPA levels was transiently observed in NPC cells at a shorter timepoint, before changes in cholesterol could be detected (Fig 6B at 48h) . In NPC mice, the effects of the drug are also likely to be masked by the beneficial decrease in storage of cholesterol and other lipids including LBPA. Consistent with previous findings [28] , we conclude that in NPC cells much like in other cell types, thioperamide increases LBPA levels, which helps buffer membrane cholesterol and reduce storage materials in endosomes. Since a very limited number of strategies only are emerging as possible treatment for NPC [31, 43, 51, 52] , we believe that our study of the FDA-approved compound thioperamide provide exciting novel perspectives for the treatment of NPC.
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METHODS
Reagents and cells
We used the following mouse monoclonal antibodies against: transferin receptor ( 
HCS Screen
The compound screen was carried out in Hela MZ cells (provided by Marino Zerial, MPI-CBG, Dresden) and A431 cells, cultured as described [14] . 
Image analysis with MetaXpress Custom Module Editor
To analyze and quantify the LBPA and free cholesterol cell content, we used the MetaXpress Custom Module editor software to first segment the image and generate relevant masks, which were then applied on the fluorescent images to extract relevant measurements. In the first step, the cell was segmented by using the nuclei (propidium iodide) channel and the 
Data analysis with AcuityXpress
All plates were annotated with the compound library using AcuityXpress. Data set were normalized (Z-score) and analyzed using the same software to generate all screen graphs and PCA. Compounds displaying more than 20% toxicity were excluded from the data analysis.
EGF receptor degradation
HeLa-MZ were starved in serum free medium for 4h and treated with 100nM EGF as indicated [54] . Cells were then fixed and stained with antibodies to the EGF receptor, followed by fluorescently labeled secondary antibodies. The EGF receptor signal was then quantified by automated microscopy using the ImageXpress® confocal microscope (Molecular Devices™) after segmentation of the granular structures containing the EGFR signal [55], using Custom
Module Editor™ from MetaXpress™. The obtained mask was then applied to the EGF receptor fluorescent micrographs and the integrated intensity (sum of all pixel intensities) is extracted for each cell (approx. 5000 cells analyzed per condition).
HRH3 stable cell
The HeLa MZ HRH3-GFP stable cell line has been generated using the gateway pLenti 6.3 V5CT vector backbone. Lentivirus have been prepared as follow: 6x10 3 HEK293T cells were seeded into 10 cm dishes pre-coated for 15min with 0.001% poly-L-lysine (1:10 dilution of 0.01% stock). Cells were incubated for 6h at 37˚C, 5% CO2 in medium containing 10% FBS before transfection. The transfection mix contained 15µl Lipofectamine 2000, plasmids (pLenti6.3-V5CT-HRH3-GFP 15μg, pLP1 10μg, pLP2 10μg, pLP-VSV-G 10μg) in OptiMEM (500µl final). The reactions were mixed and incubated for 20min at room temperature. After 48h, the medium was aspirated and exchanged with fresh medium. Then 24h later, the medium was collected, filtered (0.45μm) and directly added onto target cells (at 40% confluency). The target cells were then cultured for 48h before detecting expression. At that point, the medium was changed and cells treated with blasticidin (20ug/ml) for the first selection. Clone selection was carried out in the presence of 5µg/ml blasticidin by dilution in 384 well-plates and clones were analyzed by automated microscope.
CRISPR/Cas9 NPC1 and NPC2 KO cell lines
Guide sequences to produce NPC1 and NPC2 KO cells were obtained using the CRISPR design tool: NPC1:(fwd: CACCGCCAAGGGCCAGGCCGCGAG; rev: AAACCTCGCGGCCTGGCCCTTGGCG); NPC2:(fwd:TAATACGACTCACTATAGGTCCTTGAACTGCACC; rev:
TTCTAGCTCTAAAACAACCGGTGCAGTTCAAGGA). The sequences were used to insert the target sequence into the pX330 vector using Golden Gate Assembly (New England Biolabs) and transfected into cells. Knock-out clones were isolated by serial dilution and confirmed by RT-PCR, Western blotting and filipin staining.
RT-PCR
Total-RNA was extracted using RNeasy Mini Kit from Qiagen (ref.74104) from monolayers of
Hela according to manufacturer's recommendation. cDNA synthesis was carried out using SuperScript™ VILO™ cDNA Synthesis Kit (Life Technologies AG; Basel, Switzerland) from 250 ng of total RNA. mRNA expression was evaluated using SsoAdvanced SYBR Green Supermix 
Lipid extraction for Mass Spec
Cells (near confluency in 6-cm plastic dishes) were scraped off the dish in PBS and sedimented for analysis. Alternatively, lyophilized homogenized liver tissue (7,5 mg) were resuspended in 100μl cold water before addition of 360μl methanol and the internal standard ergosterol (20 nmol). Next, 1.2ml 2-methoxy-2-methylpropane (MTBE) was added and lipids were extracted by vortexing at 4°C for 10min followed by 1h shaking at room temperature to allow complete lipid partitioning [56] . A total of 200μl water was added to induce phase separation, and the upper phase was collected and dried. Total phosphates were quantified with an ammonium Molybdate colorimetric assay [57] .
Mass spectrometry
Membrane cholesterol and cholesteryl ester amounts were normalized and calibrated using the total phosphate content and the integrated signal of a spiked ergosterol standard, as previously described [14] . For phospholipid analysis, dried lipid samples were re-dissolved in chloroform-methanol (1:1 v/v). Separation was performed on a HILIC Kinetex column (2.6μm, 2.1 × 50mm2) on a Shimadzu Prominence UFPLC xr system (Tokyo, Japan): mobile phase A was acetonitrile:methanol 10:1 (v/v) containing 10mM ammonium formate and 0.5% formic acid; mobile phase B was deionized water containing 10mM ammonium formate and 0.5% formic acid. The elution of the gradient began with 5%B at a 200µL/min flow and increased linearly to 50% B over 7 min, then the elution continued at 50% B for 1.5 min and finally the column was re-equilibrated for 2.5 min. The sample was injected in 2µL chloroform:methanol 1:2 (v/v). Data were acquired in full scan mode at high resolution on a hybrid Orbitrap Elite (Thermo Fisher Scientific, Bremen, Germany). The system was operated at 240'000 resolution (m/z 400) with an AGC set at 1.0E6 and one microscan set at 10ms maximum injection time.
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The heated electro spray source HESI II was operated in positive mode at a temperature of 90°C and a source voltage at 4.0KV. Sheath gas and auxiliary gas were set at 20 and 5 arbitrary units respectively while the transfer capillary temperature was set to 275°C. The mass spectrometry data were acquired with LTQ Tuneplus2.7SP2 and treated with Xcalibur 4.0QF2
(Thermo Fisher Scientific). Lipid identification was carried out with Lipid Data Analyzer II (LDA v. 2.5.2, IGB-TUG Graz University) [58] . Peaks were identified by their respective retention time, m/z and intensity. Instruments were calibrated to ensure a mass accuracy lower than 3ppm. Data visualization was improved with the LCMSexplorer web tool hosted at EPFL (https://gecftools.epfl.ch/lcmsexplorer). We could clearly show the separation of LBPA from the isobaric lipid PG, as already described by others with HILIC column [59] , which allows unambiguous quantification of the two lipids ( fig. S2 ).
Enzymatic Cholesterol Quantification
Cholesterol content in liver samples was quantified enzymatically using the Amplex Red cholesterol kit assay (Molecular probes; A12216). Liver lipids extracted with MTBE were dried, resuspended in pure methanol and then directly diluted in the assay buffer. The assay in a 96-well plate format was according to the manufacturer's instructions.
Mouse lipid analysis
BALBc/NPC nih mice were bred as heterozygotes to generate Npc1 −/− mice and control genotypes. Mice were bred and housed under non-sterile conditions, with food and water available ad lib. All experiments were conducted using protocols approved by the UK Home
Office Animal Scientific Procedures Act, 1986. Npc1
and Npc1 +/+ mice (n = 6 males and 6 females) were treated with the compound in the drinking water (at 8.8 mg/L, corresponding to 2mg/kg/day). Treatment started at weaning (3 weeks of age) and mice were sacrificed at 9 weeks of age by intraperitoneal injection with an overdose of phenobarbital Care was taken to minimize suffering through euthanizing the animals once liver enlargement was unambiguously detected by visual inspection (i.e. 3 weeks after initiation of treatment).
Mouse behavioral analysis
Thioperamide was delivered as above and miglustat (600mg/kg) was administered as a dry admix in powdered chow from 3 weeks of age. The weight and spontaneous activity of each mouse was recorded weekly [60] until they reached the humane end-point (loss of 10% body weight within 24hrs). Motor function and coordination were assessed by observational counting of total rearing events recorded manually for 5min (the number of times the mouse reared on its hind legs with or without support of the cage wall). Tremor was measured [60] using a commercial tremor monitor (San Diego Instruments) according to manufacturer's instructions on an anti-vibration table. The mice were monitored for 256s, after a 30s acclimatization period. The tremor monitor was connected to a computer via National instrument PCI card and the output (amplitude/time) was analyzed using LabView software to give a measurement of power for each frequency (0-64 Hz).
Other methods
Transfection with siRNAs was performed according to manufacturers' instructions using After endocytosis by the LDL receptor, LDL are delivered to early and then late endosomes.
RNAiMAX (ThermoFisher Scientific
Free cholesterol is released in late endosomes and then exported to its cellular destinations.
(B) Screen data plot
The plot shows the integrated intensity of LBPA vs. filipin ( independent experiments with 500.000 cells analysed automatically. 
(D-E) Quantification of cell counts in the 3 NPC cell lines treated with thioperamide
The experiment was as in (A-C) except that nuclei were labelled with DAPI and quantified by automated microscopy. Data are normalzed to DMSO control. 
Npc1
−/− and Npc1 +/+ mice were treated or not with thioperamide, and liver extracts were prepared. All sLBPA species present in the extracts were quantified by LC-MS (as in Fig EV5) , The Table lists all the compounds shown in Fig 5A , which target histamine receptor family members, including those present in the Prestwick library and the additional compounds selected from the literature, which were tested separately.
EXPANDED VIEW TABLE LEGENDS
